The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

Hadji, Peyman; Stoetzer, Oliver; Decker, Thomas; Kurbacher, Christian M.; Marme, Frederik; Schneeweiss, Andreas; Mundhenke, Christoph; Distelrath, Andrea; Fasching, Peter A.; Lux, Michael P.; Lueftner, Diana; Janni, Wolfgang; Muth, Mathias; Kreuzeder, Julia; Quiering, Claudia; Grischke, Eva-Marie; Tesch, Hans

dc.contributor.author	Grischke, Eva-Maria
dc.date.accessioned	2020-06-16T12:19:09Z
dc.date.available	2020-06-16T12:19:09Z
dc.date.issued	2019
dc.identifier.issn	2212-1374
dc.identifier.uri	http://hdl.handle.net/10900/101527
dc.language.iso	en	de_DE
dc.publisher	Elsevier Science Bv	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/j.jbo.2018.09.010	de_DE
dc.subject.ddc	610	de_DE
dc.title	The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial	de_DE
dc.type	Article	de_DE
utue.quellen.id	20190926111821_02732
utue.personen.roh	Hadji, Peyman
utue.personen.roh	Stoetzer, Oliver
utue.personen.roh	Decker, Thomas
utue.personen.roh	Kurbacher, Christian M.
utue.personen.roh	Marme, Frederik
utue.personen.roh	Schneeweiss, Andreas
utue.personen.roh	Mundhenke, Christoph
utue.personen.roh	Distelrath, Andrea
utue.personen.roh	Fasching, Peter A.
utue.personen.roh	Lux, Michael P.
utue.personen.roh	Lueftner, Diana
utue.personen.roh	Janni, Wolfgang
utue.personen.roh	Muth, Mathias
utue.personen.roh	Kreuzeder, Julia
utue.personen.roh	Quiering, Claudia
utue.personen.roh	Grischke, Eva-Marie
utue.personen.roh	Tesch, Hans
dcterms.isPartOf.ZSTitelID	Journal of Bone Oncology	de_DE
dcterms.isPartOf.ZS-Issue	Article UNSP 100199	de_DE
dcterms.isPartOf.ZS-Volume	14	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE